The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours
Por:
Mato E., Barceló-Batllori S., Orera I., Selva L., Corra M., González C., Bell O., Lerma E., Moral A., Pérez J.I., de Leiva A.
Publicada:
1 ene 2015
Resumen:
We investigated the role of VDAC2 in human epithelial thyroid tumours using proteomic 2D-DIGE analysis and qRT-PCR. We found a significant up-regulation of VDAC2 in thyroid tumours and in thyroid tumour cell lines (TPC-1 and CAL-62). We did not detect overexpression of VDAC2 in a normal thyroid cell line (Nthy-ori 3-1). Silico analysis revealed that two proteins, BAK1 and BAX, had a strong relationship with VDAC2. BAK1 gene expression showed down-regulation in thyroid tumours (follicular and papillary tumours) and in TPC-1 and CAL-62 cell lines. Transient knockdown of VDAC2 in TPC-1 and CAL-62 promoted upregulation of the BAK1 gene and protein expression, and increased susceptibility to sorafenib treatment. Overexpression of the BAK1 gene in CAL-62 showed lower sorafenib sensitivity than VDAC2 knockdown cells. We propose the VDAC2 gene as a novel therapeutic target in these tumours. © 2015 Elsevier Ireland Ltd.
Filiaciones:
Mato E.:
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institut d'Investigació Biomèdica Sant Pau (IIB), Autonomous University, Barcelona, Spain
EDUAB-HSP Neoplasia Thyroid Study Group, IIB, Autonomous University, Barcelona, Spain
Barceló-Batllori S.:
Proteomics Unit, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
Orera I.:
Centro Investigaciones Biomédicas Aragón (CIBA), Inst. Arag. de Ciencias de la Salud-Inst. de Inv. Sanitaria Aragón (IACS-IIS), Zaragoza, Spain
Selva L.:
EDUAB-HSP Neoplasia Thyroid Study Group, IIB, Autonomous University, Barcelona, Spain
Corra M.:
Proteomics Unit, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
González C.:
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institut d'Investigació Biomèdica Sant Pau (IIB), Autonomous University, Barcelona, Spain
EDUAB-HSP Neoplasia Thyroid Study Group, IIB, Autonomous University, Barcelona, Spain
Bell O.:
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institut d'Investigació Biomèdica Sant Pau (IIB), Autonomous University, Barcelona, Spain
EDUAB-HSP Neoplasia Thyroid Study Group, IIB, Autonomous University, Barcelona, Spain
Lerma E.:
Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University, Barcelona, Spain
Moral A.:
General Surgery, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
Pérez J.I.:
General Surgery, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
de Leiva A.:
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institut d'Investigació Biomèdica Sant Pau (IIB), Autonomous University, Barcelona, Spain
EDUAB-HSP Neoplasia Thyroid Study Group, IIB, Autonomous University, Barcelona, Spain
|